Drugs / Ceftazidime/Avibactam
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03790176 | Oct 2018 → Dec 2022 | peritonitis, pneumonia | Markus Zeitlinger | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ceftazidime/Avibactam | “Ceftazidime/Avibactam (CAZ/AVI) is a novel antibiotic drug that has recently become available.” NCT03790176 ↗ |
| Known as | CAZ/AVI | “Ceftazidime/Avibactam (CAZ/AVI) is a novel antibiotic drug that has recently become available.” NCT03790176 ↗ |
| Route | Intravenous | “one single intravenous infusion of ceftazidime/avibactam (CAZ/AVI) 2g/0.5g over two hours” NCT03790176 ↗ |